← Eichor
Study identifier: NCT06676007 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy

Condition: IgA Nephropathy (IgAN) · Early Initial Therapy  ·  Sponsor: Sichuan Provincial People's Hospital

PhaseN/A
Planned participants200
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

To observe of the efficacy and safety of early initiation of budesonide enteric coated capsules in the treatment of primary IgA nephropathy.

This description comes directly from the study's public registry record.

Talk to the study team

Guisen Li, Doctor  ·  +86-28-87393340  ·  guisenli@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Sichuan Provincial People's HospitalChengdu, Sichuan, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06676007